Medicare utilization — DR. SUJATHA YELLINEDI (M.D.)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 34,680 | 53 | $0 | $13,300 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 12,600 | 15 | $0 | $714 |
| J9271 | Injection, pembrolizumab, 1 mg | 4,400 | 13 | $0 | $189,981 |
| J0897 | Injection, denosumab, 1 mg | 4,320 | 26 | $0 | $80,022 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,450 | 45 | $0 | $142 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·